Bloomberg News reported on Nov. 15, 2023, that QuidelOrtho was considering a sale of its transfusion medicine unit, with people familiar with the matter indicating a potential valuation of about $1.5 billion to $2.0 billion.
The report said the review was at an early stage, with no certainty that a transaction would proceed, and that the business could draw interest from both strategic buyers and private equity firms.
In later filings, QuidelOrtho said the former transfusion medicine business unit is now presented as immunohematology and donor screening following the wind-down of its U.S. donor screening portfolio. The company reported 2025 revenue of $543.8 million for immunohematology and $52.6 million for donor screening, compared with $522.6 million and $115.5 million, respectively, in 2024.
QuidelOrtho also disclosed in its 2025 annual report that management may divest, spin off, or discontinue certain operations as part of portfolio actions.